Ignazio Di Giovanna

Vice President- Scientific Affairs, Neurology Evestia Clinical

Dr. Ignazio Di Giovanna, ARG Vice-President of Europe, has deep experience in the clinical research domain, having worked in the CRO field since 1990 and the pharmaceutical industry as a whole since 1986. Previously, Ignazio owned and operated the European CRO CCA Clinical Research, from 1999 until its acquisition by ARG in 2018.

Ignazio was a board member at the Institute of Clinical Research (1999-2006) and Chair from 2004 – 2006. Ignazio is past-President of the Clinical & Contract Research Association (CCRA) and a member of the Biotechnology & Pharmaceuticals Sector Advisory Group (BPSAG), advising and influencing UKTI on trade and investment matters for the sector to help improve the UK market.

Ignazio was co-editor of “Principles in Clinical Research,” published in 2001, and in April 2004 was awarded an Honorary Fellowship by the Institute of Clinical Research. Ignazio earned a PhD in Biophysics at Guys Hospital, based on the development of non-invasive cardiovascular diagnosis techniques.

Seminars

Wednesday 3rd June 2026
Panel Discussion: Given Recent Failures, How Can We Tailor ALS Clinical Trials to Successfully Meet Regulatory Expectations
1:40 pm
  • Outlining the approval path for sporadic and familial ALS: is it the same for different modalities? What is the regulatory bar for approving this?
  • Harnessing innovative trial design
  • Cross comparing diverging requirements for different regulatory agencies including the FDA, EMA and more
  • Establishing clear, patient-relevant endpoints and leveraging biomarkers to demonstrate efficacy
  • Critically identifying stumbling blocks in IND and BLA packages to circumvent late-stage failures and pitfalls in drug development
Ignazio de Giovanni, Vice President, Scientific Affairs, Neurology, Evestia Clinical - Expert Speaker at the 5th ALS Drug Development Summit 2026